AccurEdit Therapeutics Raises $75M Series A to Advance CRISPR Gene Editing Pipeline

SUZHOU, China, Feb. 3, 2026 — AccurEdit Therapeutics, a Suzhou-based gene editing startup, has raised $75 million in a Series A financing to advance its expanding pipeline of CRISPR-based therapies, marking one of the largest funding rounds to date for a Chinese gene editing company. The financing closed in September, bringing AccurEdit’s total funding to $116 million since its founding in 2021.

AccurEdit has positioned itself at the forefront of in vivo gene editing in China. In August 2023, the company became the first in the country to treat a patient with an in vivo CRISPR therapy, administered through an investigator-initiated study approved by hospitals rather than national regulators. The company has since generated clinical data across multiple cardiovascular indications.

In its lead transthyretin amyloidosis (ATTR) program, AccurEdit reported that the highest tested dose achieved more than a 90% reduction in circulating transthyretin protein within four weeks, with effects remaining stable for at least 72 weeks. The company reported lower rates of liver enzyme elevations compared with similar therapies developed by Western competitors. A Phase 2 study is ongoing in China, and a Phase 1 study has been cleared in the United States.

AccurEdit’s second program targets PCSK9, a well-established gene associated with LDL cholesterol levels. The company reported reductions of nearly 62% in LDL-C and 88% in PCSK9 protein at higher dose levels, exceeding results disclosed by comparable programs. AccurEdit has treated approximately 40 patients across its cardiovascular gene editing studies to date.

Beyond cardiovascular disease, AccurEdit is expanding into in vivo CAR-T therapies using lipid nanoparticles to reprogram immune cells directly inside the body, with plans to initiate human studies this year. The company is also developing a gene editing program targeting HSD17B13 for metabolic dysfunction-associated steatohepatitis (MASH), aiming for a permanent therapeutic solution rather than chronic treatment.

The newly raised capital is expected to fund operations for approximately three years and support advancement of at least two programs into Phase 2 studies and one program into Phase 3 clinical development.